[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"copd-bronchitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:copd-bronchitis":134},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,75,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100565808","comparison-of-several-oxygenation-targets-with-different-oxygen-interfaces---impact-on-oxygen-flow-rates-100565808",false,"NCT06646991","Comparison of Several Oxygenation Targets With Different Oxygen Interfaces - Impact on Oxygen Flow Rates","Interfaces","Inclusion Criteria:\n\n* Adult (\\> or = 18 years old)\n* Ongoing on conventional oxygen therapy with peripheral oxygen saturation (SpO2) between 88 and 100% with the usual oximeter\n* SpO2 \\\u003C 92% ambient air with the usual oximeter\n\nExclusion Criteria:\n\n* No SpO2 signal with with the usual oximeter\n* False nails or nail polish\n* Severe anemia documented on last blood count during current hospitalization (haemoglobin (Hb) \\\u003C 80g\u002FL)\n* Oxygen flow \\> 6 L\u002Fmin","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","Oxygen therapy is at the heart of the healthcare system. Oxygen flow rates depend on a number of confounding factors confounding factors (target used, skin pigmentation, pulse oximeter used, etc.) The investigators have recently have recently demonstrated that the combination of these factors (different peripheral oxygen saturation (SpO2) targets and different oximeters) can have a significant impact on oxygen flows rates. The effect on oxygen flow was not simply additive .\n\nThe aim of this study is to evaluate the impact of the interface used on oxygen flow rates in different patient populations (main objective). The investigatoers also evaluate the impact of the interface on carbon dioxide (PaCO2), in particular with closed oxygen masks, with which rebreathing is theoretically possible (secondary objective).\n\nsecondary objective).",[26,27,28],"Oxygen Toxicity","COPD Bronchitis","Respiratory Failure","NOT_YET_RECRUITING","2024-11-20",{"date":32,"type":33},"2024-11-22","ACTUAL",{"date":35,"type":20},"2024-12",{"date":37,"type":20},"2025-12",{"name":39,"class":40},"Laval University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":41},"100560038","phase-4-effect-of-the-inhaled-triple-therapies-over-the-small-airway-in-biomass-exposure-100560038","NCT06571942","Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure","Effect of the Inhaled Triple Therapies Over the Small Airway in Patients With Chronic Obstructive Pulmonary Disease or Chronic Bronchitis Without Obstruction Secondary to Biomass Exposure: Randomized Controlled Clinical Trial Phase IV","Inclusion Criteria:\n\n* Subject capable of understanding instructions and giving her consent for participation.\n* Diagnosis of COPD or chronic bronchitis without obstruction due to biomass smoke exposure:\n\n  1. Diagnosis of COPD according to GOLD guidelines 2023 with: \\>100 hours-year of biomass exposure index, and with a post-bronchodilator spirometry FEV1 \\> 70% of predicted value.\n  2. Diagnosis of Chronic Bronchitis without obstruction with at least \\>100 hours-year of biomass smoke exposure index or more than 10 years of continued exposure to biomass smoke, and with 1) antecedent of chronic bronchitis, and 2) post-bronchodilator spirometry FEV1\u002FFVC \\>0.7.\n* Able to attend all visits.\n* Cooperative patients with adequate understanding and skill in using inhalers, or with caregivers capable of administering medications and filling out a daily symptom diary.\n* Stable patients, with no history of exacerbations in the last 4 weeks before inclusion.\n\nExclusion Criteria:\n\n* Pregnancy or in the breastfeeding period.\n* Documented allergy or intolerance to any of the study medications.\n* History of clinically significant bronchiectasis, tuberculosis, recent respiratory infection (4 weeks), or cardiovascular comorbidity that contraindicates pulmonary function tests or that influences their status and functional class.\n* Patients with suspicion or history of cancer.\n* Uncontrolled diseases: acute hyperthyroidism, acute uncontrolled DM2, acid-peptic disease that causes bleeding, uncontrolled hematological diseases, etc. In general, any decompensated disease that, in the opinion of the principal investigator, may influence the results of the study.","FEMALE","35 Years","85 Years",{"count":53,"type":20},128,[55],"PHASE4","This phase IV randomized controlled clinical trial intend to compare the effect of three close standard inhaled triple therapies and one close standard inhaled double therapy on the small airway in patients with Chronic Obstructive Pulmonary Disease (COPD-B) and chronic bronchitis without obstruction (BCNO) exposed to wood smoke. The treatment phase duration is of 3 months. As primary outcome, the resistance change in post-bronchodilatator impulse oscilometry will me measure at 30 minutes, 2 hours, 4 hours, and 24 hours post first dose of the asigned medication, and then at 1 and 3 months of treatment. As secondary outcomes, change in respiratory symptoms and health related quality of life will be assess after 1 and 3 months of treatment.",[27,58],"Pollution Related Respiratory Disorder",[60,61,62,63],"Biomass","COPD","Chronic bronchitis","Inhaled therapy","RECRUITING","2024-08-25",{"date":67,"type":33},"2024-08-26",{"date":69,"type":33},"2023-11-15",{"date":71,"type":20},"2025-01-15",{"name":73,"class":74},"National Institute of Respiratory Diseases, Mexico","OTHER_GOV",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100478228","phase-2-effects-of-blocking-tslp-on-airway-inflammation-and-the-epithelial-immune-response-to-exacerbation-triggers-in-patients-with-copd-100478228","NCT05507242","Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD","Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD A Randomized Double-blind, Placebo-controlled Trial of Tezepelumab UPSTREAM-COPD","UPSTREAM-COPD","Inclusion Criteria:\n\n* Written informed consent\n* A diagnosis of COPD (according to GOLD (GOLD 2021 Report))\n* ≥ 10 packyears smoked (current or ex-smokers)\n* Age 40 years or older\n* Postbronchodilator FEV1 ≥ 30% predicted (and ≥ 1.0L) and \\\u003C 80% predicted\n* Maintenance treatment with LAMA+LABA±ICS (stable dose) for at least 3 months prior to V1\n* ≥1 prednisolon and\u002For antibiotic treated exacerbation in the past 12 months\n* Subjects must demonstrate acceptable inhaler and spirometry techniques during screening (as evaluated and in the opinion of study site staff)\n* Subjects must demonstrate ≥ 70% compliance with daily inhalers during the screening\u002Frun-in\n* Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception from the time informed consent is obtained and must agree to continue using such precautions through Week 20 of the study; cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause).\n\nExclusion Criteria:\n\n* Previous medical history or evidence of an uncontrolled intercurrent illness that in the opinion of the investigator may compromise the safety of the subject in the study or interfere with evaluation of the investigational product or reduce the subject's ability to participate in the study. Subjects with well-controlled comorbid disease (eg, hypertension, hyperlipidemia, gastroesophageal reflux disease) on a stable treatment regimen for 15 days prior to Visit 1 are eligible.\n* Any concomitant respiratory disease that in the opinion of the investigator will interfere with the evaluation of the investigational product or interpretation of subject safety or study results (e.g., cystic fibrosis, pulmonary fibrosis, aspergillosis, active tuberculosis).\n* Current asthma\n* Lung volume reduction surgery for COPD\n* Exacerbation requiring oral corticosteroids or antibiotics (any dose for more than 3 days) 4 weeks prior to Visit 1 or during the run-in period\n* Any use of home oxygen therapy\n* Any clinically relevant abnormal findings in hematology or clinical chemistry (laboratory results from Visit 1), physical examination, vital signs during the screening, which in the opinion of the investigator, may put the subject at risk because of his\u002Fher participation in the study, or may influence the results of the study, or the subject's ability to participate in the study\n* History of cancer: Subjects who have had basal cell carcinoma or in situ carcinoma of the cervix are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to Visit 1. Subjects who have had other malignancies are eligible provided that curative therapy was completed at least 5 years prior to Visit 1.\n* Acute upper or lower respiratory infections requiring antibiotics or antiviral medications within 4 weeks prior to Visit 1 or during the screening period\n* A positive human immunodeficiency virus (HIV) test at screening or subject taking antiretroviral medications, as determined by medical history\n* Positive hepatitis B surface antigen, or hepatitis C virus antibody serology at screening, or a positive medical history for hepatitis B or C. Subjects with a history of hepatitis B vaccination without history of hepatitis B are allowed to enroll.\n* History of sensitivity to any component of the investigational product formulation or a history of drug or other allergy that, in the opinion of the investigator or medical monitor contraindicates their participation.\n* History of any known primary immunodeficiency disorder excluding asymptomatic selective immunoglobulin A or IgG subclass deficiency.\n* Active tuberculosis or history of untreated latent tuberculosis\n* History of anaphylaxis to any biologic therapy.\n* Use of immunosuppressive medication (eg, methotrexate, troleandomycin, oral gold, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid, or any experimental anti-inflammatory therapy) within 3 months prior to Visit 1.\n* Receipt of any of the following within 30 days prior to Visit 1: immunoglobulin or blood products, or receipt of any investigational nonbiologic agent within 30 days or 5 half-lives prior Visit 1, whichever is longer.\n* Receipt of any marketed or investigational biologic agent within 4 months or 5 half- lives prior to Visit 1, whichever is longer.\n* Pregnant, breastfeeding or lactating females\n* History of chronic alcohol or drug abuse within 12 months prior to Visit 1.\n* Planned surgical procedures requiring general anesthesia or in-patient status for \\> 1 day during the conduct of the study.\n* Unwillingness or inability to follow the procedures outlined in the protocol.\n* Concurrent enrollment in another clinical study involving an investigational treatment.\n* Receipt of any live or attenuated vaccines within 15 days prior to Visit 1.","40 Years",{"count":85,"type":20},80,[87],"PHASE2","A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in patients with COPD.",[61,90,27,91,92],"COPD Exacerbation","Airway Disease","Immune System Disorder",[61],"2024-08-19",{"date":96,"type":33},"2024-08-21",{"date":98,"type":33},"2022-10-25",{"date":100,"type":20},"2025-12-31",{"name":102,"class":40},"Asger Sverrild",2,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":41},"100539466","telehealth-and-onsite-maintenance-exercise-in-chronic-lung-disease-100539466","NCT06304207","Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease","Comparison of Telehealth and Onsite Supervised Maintenance Exercise Program for Adults With Chronic Lung Disease: A Pilot Randomized Controlled Trial","CLD","Inclusion Criteria:\n\n* All adult patients 40 years and older with physician diagnosed Chronic Lung Disease within 2 months of discharge following completion of a traditional onsite outpatient rehabilitation or physical therapy or exercise program for their condition\n* Able to walk independently with or without mobility devices\n* Able to complete a six-minute walk test at discharge with or without supplemental oxygen maintaining an oxygen saturation at or above 85%\n* Able to follow commands and instructions in the English language\n* Have ability to connect to the internet\n\nExclusion Criteria:\n\n* • Those with significant mobility limitations such as those with a history of stroke, neurological comorbidities such as Parkinson's disease or relapsing multiple sclerosis, or significant degenerative osteoarthritis, or any other joint impairments that compromise ability to walk independently with or without an assistive device.\n\n  * Patients who primarily rely on a wheelchair for mobility\n  * Patients with or without supplemental oxygen who are unable to complete a walking test without a drop in oxygen saturation to below 85% at discharge from traditional outpatient rehabilitation\n  * Patients with baseline hemodynamic compromise, unstable angina, a recent myocardial infarction within a week, uncontrollable atrial fibrillation not managed with medications, advanced stage heart failure (New York Heart Association class 4), or those with mechanical circulatory assist devices for the heart such a ventricular assist device (VADs)\n  * Inability to communicate in the English language",{"count":113,"type":20},30,[23],"The goal of this pilot clinical trial is to compare telehealth and onsite supervised maintenance exercise program for adults with Chronic Lung Disease.\n\nThe specific aims of the study are:\n\n* To compare 8-week supervised maintenance program delivered onsite and via tele-rehab with no maintenance for patients with Chronic Lung Disease following discharge from traditional exercise or physical therapy or onsite outpatient rehabilitation programs on clinical outcomes (dyspnea, exercise capacity, physical function, physical activity, and quality of life) at 8 weeks and 4-months post-intervention.\n* To compare the differences in dyspnea, exercise capacity, physical function, physical activity, and quality of life between an 8-week maintenance program delivered onsite and via tele-rehab at 8-weeks and 4-months post-intervention in patients with Chronic Lung Disease following discharge from traditional onsite outpatient rehabilitation.\n\nParticipants in both intervention groups (onsite and tele-rehab) will undergo a baseline onsite assessment followed by an 8-week supervised exercise intervention either onsite or in a telehealth setting. Control group will receive biweekly check in calls, but no active intervention.",[117,90,27,118,119,120,121,122,123,124],"Copd","Emphysema or COPD","Chronic Lung Disease","Pulmonary Fibrosis","Interstitial Lung Disease","Bronchiectasis","Chronic Asthma","Chronic Asthmatic Bronchitis","2024-07-30",{"date":127,"type":33},"2024-08-01",{"date":129,"type":33},"2023-09-01",{"date":131,"type":20},"2026-03-01",{"name":133,"class":40},"MGH Institute of Health Professions","Copd Bronchitis"]